Clearmind Medicine Completes Treatment and Follow-Up for 18 Participants in AUD Trial.

Clearmind Medicine has completed treatment and follow-up for 18 participants in its Phase 1/2a clinical trial for CMND-100, a non-hallucinogenic drug candidate for Alcohol Use Disorder. The trial aims to evaluate safety, tolerability, and efficacy of CMND-100. The company's Tel Aviv clinical site has also added four more participants, demonstrating operational strength. The trial is being conducted at leading institutions, including Yale University and Johns Hopkins University.